RxDoctor Payments Data

Darlene Wilson, APRN

Family · Booneville, KYNPI 1528160066

Payments from drug & device makers

$531in general payments, 2019–2025

Across 31 payments — averaging $17.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$159
  • Kowa Pharmaceuticals America, Inc.$88
  • GSK$61
  • Pfizer$57
  • Vanda Pharmaceuticals Inc.$41
  • AstraZeneca$37
  • plus $89 from 6 others

What the payments were for

  • Food & beverage$531100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$531 in reported general payments places this provider in the 50th percentile of 4,374 family providers in Kentucky.

See all family providers in Kentucky

Medicare billing

Part B allowed, 2024
$23,839
Medicare patients
14
Services billed
370

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide76$81,709
OzempicSemaglutide63$61,742
JanuviaSitagliptin Phosphate50$33,470
JardianceEmpagliflozin29$27,902
EliquisApixaban46$26,014
FarxigaDapagliflozin Propanediol17$16,732
VascepaIcosapent Ethyl33$16,541
Spiriva RespimatTiotropium Bromide17$15,541
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen1,268$15,266
LinzessLinaclotide21$13,548
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr19$11,644
Trelegy ElliptaFluticasone/Umeclidin/Vilanter19$11,571
LivaloPitavastatin Calcium31$9,922
Combivent RespimatIpratropium/Albuterol Sulfate21$9,616
Albuterol Sulfate HfaAlbuterol Sulfate264$9,561

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Spiriva Respimat, Combivent Respimat$14$53,05967 claims
PfizerEliquis$57$26,01446 claims
GSKAnoro Ellipta, Trelegy Ellipta$61$23,21538 claims
AstraZenecaFarxiga, Symbicort$37$19,67028 claims
Kowa Pharmaceuticals America, Inc.Livalo$88$9,92231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 4,374 family providers in Kentucky.

Other family in Booneville

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →